Durvalumab: all 557 studies that test it
Page 1 of 6. Open to participants first (117), then studies with results posted, then the rest; newest registration first within each.
- A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.Not yet recruitingNCT07877818Phase 3
- A Prospective, Multi-Center, Phase 4, Single Arm Study To Assess The Safety and Tolerability of Perioperative Durvalumab in Combination With Neoadjuvant Gemcitabine Plus Cisplatin in Indian Patients With Muscle-Invasive Bladder Cancer Cle-InvasiveNot yet recruitingNCT07876817Phase 4
- Zolbetuximab, Durvalumab, and FLOT Combination Neoadjuvant Chemotherapy for CLDN18.2-Positive Gastric Cancer or Gastroesophageal Junction AdenocarcinomaRecruitingNCT07872722Phase 2
- Histotripsy in Biliary Tract CancerRecruitingNCT07853690Not applicable
- Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or CholangiocarcinomaRecruitingNCT07780838Phase 2
- Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic CholangiocarcinomaRecruitingNCT07766187Phase 2
- DURATION-GC: FLOT Plus Durvalumab and TS-1 Plus Durvalumab for Resectable Gastric CancerNot yet recruitingNCT07757191Phase 2
- Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular CarcinomaNot yet recruitingNCT07511504Phase 2
- TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal AdenocarcinomaNot yet recruitingNCT07507968Phase 2
- A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLCRecruitingNCT07459634Phase 2
- A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous DurvalumabRecruitingNCT07391670Phase 1
- Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung CancerRecruitingNCT07339059Phase 2
- Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA TrialNot yet recruitingNCT07332351Phase 2
- Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP TrialRecruitingNCT07288034Phase 2
- Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular CancerNot yet recruitingNCT07226063Phase 2
- Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver CancerRecruitingNCT07174570Phase 2
- Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung CancerRecruitingNCT07149363Phase 2
- Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein ThrombosisRecruitingNCT07122089Phase 2
- FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular CarcinomaRecruitingNCT07012798Phase 2
- Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCCRecruitingNCT06999707Phase 2
- Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCCRecruitingNCT06999694Phase 2
- Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLCNot yet recruitingNCT06998719Phase 2
- Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology AgentsRecruitingNCT06963346Phase 1
- Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast CancerRecruitingNCT06954480Phase 2
- Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular CarcinomaRecruitingNCT06911255Phase 1/2
- Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung CancerRecruitingNCT06890598Phase 3
- Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)RecruitingNCT06859684Phase 2
- A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinomaNot yet recruitingNCT06855225Phase 2
- ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a MuRecruitingNCT06824363Early Phase 1
- A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or RearrangementRecruitingNCT06728410Phase 2
- Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract CancerRecruitingNCT06708858Phase 2
- Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)RecruitingNCT06698250Phase 2
- Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingNCT06692491Phase 2
- Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC RegimenRecruitingNCT06680050Phase 2
- NEoadjuvant Olaparib Combination OvArian Cancer Targeted StudyNot yet recruitingNCT06650709Phase 2
- Perioperative Therapies in Locally Advanced Unresectable Gastric CancerRecruitingNCT06630130Phase 2
- A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract CancersRecruitingNCT06611345Not applicable
- Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder CancerRecruitingNCT06591650Phase 2
- Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)RecruitingNCT06564623Phase 1
- A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)RecruitingNCT06551142Phase 1
- CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract CancersRecruitingNCT06548412Phase 1/2
- Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract CancerRecruitingNCT06546969Phase 1
- Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract CarcinomaNot yet recruitingNCT06530823Phase 2
- Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B CirrhosisRecruitingNCT06526104Phase 2
- A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast CancerRecruitingNCT06508216Phase 1/2
- A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder CancerRecruitingNCT06503614Phase 2
- Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT TrialRecruitingNCT06498635Phase 3
- Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.RecruitingNCT06492421Phase 2
- Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.RecruitingNCT06492408Phase 2
- Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular CarcinomaRecruitingNCT06470256Phase 1
- AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMARecruitingNCT06464068Phase 2
- Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)RecruitingNCT06441747Phase 2
- Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extra- and Intrahepatic CholangiocarcinomaRecruitingNCT06440993Phase 2
- Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)Enrolling by invitationNCT06419179Phase 2
- Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC)RecruitingNCT06418087Phase 2
- FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and PlatinumRecruitingNCT06393816Phase 2
- Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological TherapyRecruitingNCT06375915Phase 2
- Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)RecruitingNCT06371482Phase 2
- Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNomaRecruitingNCT06341764Phase 2
- Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation, Immuno-oncology and ResectionRecruitingNCT06331455Phase 2
- Evaluating PD-1/PD-L1 in Locally Advanced Rectal Cancer by Quantitative Fluorescence Molecular EndoscopyNot yet recruitingNCT06304597Phase 1
- A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO StudyRecruitingNCT06290505Phase 2
- Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based TherapyRecruitingNCT06263153Phase 2
- Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract CancerNot yet recruitingNCT06255262Phase 1/2
- Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLCRecruitingNCT06223711Phase 2
- BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular CarcinomaNot yet recruitingNCT06111326Phase 1/2
- A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)RecruitingNCT06103864Phase 3
- Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction AdenocarcinomaRecruitingNCT06078709Phase 2
- First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine CarcinomaRecruitingNCT06070740Phase 2
- Durvalumab and Oleclumab in Resectable PDACRecruitingNCT06060405Phase 2
- Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic CholangiocarcinomaRecruitingNCT06058663Phase 1
- Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerRecruitingNCT06058377Phase 3
- Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological ImmunotherapieRecruitingNCT06031233Phase 4
- Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)RecruitingNCT05845450Phase 2
- Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) PatientsRecruitingNCT05844046Phase 2
- Immunotherapy and Radioembolisation for Metastatic Hepatocellular CarcinomaRecruitingNCT05809869Phase 2
- TRUDI: TDXD+Durva in HER2+/Low IBCRecruitingNCT05795101Phase 2
- IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)RecruitingNCT05742607Phase 2
- Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)RecruitingNCT05733689Phase 1
- Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBCRecruitingNCT05720260Phase 2
- Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung CancerRecruitingNCT05696782Phase 2
- Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence RiskRecruitingNCT05672537Phase 2
- Y-90 With Durvalumab/Gem/Cis in Intrahepatic CholangioRecruitingNCT05655949Phase 2
- Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract CancerRecruitingNCT05640791Phase 2
- Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)RecruitingNCT05620628Phase 2
- Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-PaclitaxelRecruitingNCT05582538Phase 2
- Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and DurvalumabRecruitingNCT05568212Phase 2
- Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With OligometastasesNot yet recruitingNCT05484583Phase 2
- Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With DurvalumabEnrolling by invitationNCT05303532Phase 3
- Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular FeaturesRecruitingNCT05255653Phase 3
- Olaparib with or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based ChemotherapyRecruitingNCT05222971Phase 2
- Triplex Checkpoint Inhibitors Therapy for Advanced Solid TumorsRecruitingNCT05187338Phase 1/2
- Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC.RecruitingNCT05128630Phase 2
- Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)RecruitingNCT05068232Phase 2
- Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung CancerRecruitingNCT05061550Phase 2
- Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian CancerRecruitingNCT04918186Phase 2
- WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOCRecruitingNCT04644289Phase 2
- Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract CancerRecruitingNCT04628767Phase 2/3
- A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLCRecruitingNCT04550104Phase 1
- The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD)Not yet recruitingNCT04517227Not applicable